CA125 over‐release behavior following a 75‐gram oral glucose test as a predictive biomarker of multidrug resistance in patients with ovarian cancer

Multidrug resistance is a major cause of death in patients with ovarian cancer. To improve patient survival, we developed a novel, noninvasive and convenient tool, the 75‐gram oral glucose (75gOG)‐stimulated CA125 test, to monitor cancer chemoresistance in real time. Our in vitro proof‐of‐principal experiments revealed that post‐75gOG glucose and insulin peaks can synergistically increase cancer‐derived CA125 levels, and the increase in CA125 secretion (ΔCA125) is correlated with the overactivation of the insulin receptor (IR)‐PI3K‐Akt axis and increases (ΔIC₅₀s) in cisplatin/taxol IC₅₀s. Correspondingly, among the 93 patients enrolled, post‐75gOG CA125 over‐release (i.e., enhanced ΔCA125) behavior was associated with overexpression of the IR‐PI3K‐Akt pathway and its downstream components, namely, IR, pAkt, pS6 and GLUT4, in cancer specimens. Furthermore, both pre‐ and postsurgical 75gOG CA125 tests demonstrated that CA125 over‐release showed excellent prediction efficacy on the chemoresistance potential of ovarian cancer; notably, the former indicated the need for an optimal debulking surgery, and the latter suggested the use of IR‐PI3K‐Akt inhibitors. Both test results possess independent prognostic significance for the 2‐year progression‐free survival (PFS) and overall survival (OS) of patients. The odds ratios and corresponding 95% confidence intervals (95% CIs) were 2.680 (95% CI: 1.393‐5.156) for patients with CA125 over‐release behavior evidenced by a presurgical 75gOG CA125 test or 3.822 (95% CI: 1.942‐7.522) for that evidenced by a postsurgical test in PFS; and 3.320 (95% CI: 1.508‐7.309) for patients with CA125 over‐release behavior evidenced by a presurgical test or 5.212 (95% CI: 2.241‐12.121) for that evidenced by a postsurgical test in OS.

This article is protected by copyright. All rights reserved.

https://ift.tt/2tDUzMv